I agree that this site is using cookies. You can find further informations here.
X
Printz, Marie A.
39  results:
Search for persons X
?
1

Modeling the subcutaneous pharmacokinetics of antibodies co..:

Nolan, Ryan P. ; Printz, Marie A.
Clinical and Translational Science.  17 (2024)  4 - p. , 2024
Link: https://doi.org/10.1111/..
 
?
2

Risk Factors, Hyaluronidase Expression, and Clinical Immuno..:

Printz, Marie A. ; Sugarman, Barry J. ; Paladini, Rudolph D....
The AAPS Journal.  24 (2022)  6 - p. , 2022
Link: https://doi.org/10.1208/..
 
?
3

Dispersive effects and focused biodistribution of recombina..:

Kang, David W. ; Bittner, Beate ; Sugarman, Barry J....
PLOS ONE.  16 (2021)  7 - p. e0254765 , 2021
Link: https://doi.org/10.1371/..
 
?
4

Safety of recombinant human hyaluronidase PH20 for subcutan..:

Knowles, Stephen P. ; Printz, Marie A. ; Kang, David W...
Expert Opinion on Drug Delivery.  18 (2021)  11 - p. 1673-1685 , 2021
Link: https://doi.org/10.1080/..
 
?
5

A Phase I Study to Evaluate the Safety, Tolerability, Pharm..:

Printz, Marie A. ; Dychter, Samuel S. ; DeNoia, Emanuel P....
Current Therapeutic Research.  93 (2020)  - p. 100604 , 2020
Link: https://doi.org/10.1016/..
 
?
6

PH20 is not expressed in murine CNS and oligodendrocyte pre..:

Marella, Mathieu ; Ouyang, Joe ; Zombeck, Jonathan...
Annals of Clinical and Translational Neurology.  4 (2017)  3 - p. 191-211 , 2017
Link: https://doi.org/10.1002/..
 
?
7

Clinical Immunogenicity of rHuPH20, a Hyaluronidase Enablin..:

Rosengren, Sanna ; Dychter, Samuel S. ; Printz, Marie A....
The AAPS Journal.  17 (2015)  5 - p. 1144-1156 , 2015
Link: https://doi.org/10.1208/..
 
?
8

Erratum to: Clinical Immunogenicity of rHuPH20, a Hyaluroni..:

Rosengren, Sanna ; Dychter, Samuel S. ; Printz, Marie A....
The AAPS Journal.  17 (2015)  6 - p. 1523-1524 , 2015
Link: https://doi.org/10.1208/..
 
?
9

Tolerability and Pharmacokinetic Properties of Ondansetron ..:

Dychter, Samuel S. ; Harrigan, Rena ; Bahn, Jesse D....
Clinical Therapeutics.  36 (2014)  2 - p. 211-224 , 2014
Link: https://doi.org/10.1016/..
 
?
10

EXPRESSION, BIOACTIVITY, AND SAFETY 1 YEAR AFTER ADENO-ASSO..:

Herzog, Christopher D. ; Brown, Lamar ; Gammon, Dawn...
Neurosurgery.  64 (2009)  4 - p. 602-613 , 2009
Link: https://doi.org/10.1227/..
 
?
11

AAV2-mediated delivery of human neurturin to the rat nigros..:

Gasmi, Mehdi ; Brandon, Eugene P. ; Herzog, Christopher D....
Neurobiology of Disease.  27 (2007)  1 - p. 67-76 , 2007
Link: https://doi.org/10.1016/..
 
?
12

Engineering of Tooth-Supporting Structures by Delivery of P..:

Jin, Qiming ; Anusaksathien, Orasa ; Webb, Sarah A..
Molecular Therapy.  9 (2004)  4 - p. 519-526 , 2004
Link: https://doi.org/10.1016/..
 
?
13

Adenovirus Encoding Human Platelet-Derived Growth Factor-B ..:

Gu, Dan-ling ; Nguyen, Thanh ; Gonzalez, Ana Maria...
Molecular Therapy.  9 (2004)  5 - p. 699-711 , 2004
Link: https://doi.org/10.1016/..
 
?
14

Matrix Immobilization Enhances the Tissue Repair Activity o..:

Doukas, John ; Chandler, Lois A. ; Gonzalez, Ana Maria...
Human Gene Therapy.  12 (2001)  7 - p. 783-798 , 2001
Link: https://doi.org/10.1089/..
 
?
15

Fibroblast Growth Factor 2-Retargeted Adenoviral Vectors Ex..:

Printz, Marie A. ; Gonzalez, Ana Maria ; Cunningham, Mark...
Human Gene Therapy.  11 (2000)  1 - p. 191-204 , 2000
Link: https://doi.org/10.1089/..
 
1-15